Harter, P, Bidzinski, M, Colombo, N, Floquet, A, Rubio Perez, M J, Kim, J-W, Lheureux, S, Marth, C, Nyvang, G-B, Okamoto, A, Reuss, A, Scambia, G, Trillsch, F, Vardar, M A, Van Nieuwenhuysen, E, Lichfield, J, Rugman, P, Twumasi-Ankrah, P & Aghajanian, C 2019, ' DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients ', Journal of Clinical Oncology, vol. 37, no. 15 Supplement, TPS5598 . https://doi.org/10.1200/JCO.2019.37.15suppl.TPS5598
Mirza, M R, Avall-Lundqvist, E, Birrer, M J, Christensen, R D, Nyvang, G-B, Malander, S, Anttila, M, Werner, T L, Lund, B, Lindahl, G, Hietanen, S, Peen, U, Dimoula, M, Roed, H, Knudsen, A O, Boufercha, L, Staff, S, Vistisen, A K, Bjorge, L & Maenpaa, J U 2019, ' Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24. ', Journal of Clinical Oncology, vol. 37, no. 15, Suppl., 5505 . https://doi.org/10.1200/JCO.2019.37.15suppl.5505 Mirza, M R, Avall-Lundqvist, E, Birrer, M J, Christensen, R D, Nyvang, G-B, Malander, S, Anttila, M, Werner, T L, Lund, B, Lindahl, G, Hietanen, S, Peen, U, Dimoula, M, Roed, H, Knudsen, A O, Boufercha, L, Staff, S, Vistisen, A K, Bjorge, L & Maenpaa, J U 2019, ' Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24 ', Journal of Clinical Oncology, vol. 37, no. 15 Supplement, pp. 5505-5505 . https://doi.org/10.1200/JCO.2019.37.15suppl.5505